Saint Peters, MO, United States of America

David W Berberich

This inventor holds 28 USPTO granted patents and 5 published patent applications, plus 8 CIPO patents and 20 EPO patents, primarily in Morphinan Chemistry. Top assignee: Mallinckrodt, Inc.. Active years: 2010-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David W Berberich. Retrieved from https://idiyas.com/inventor/david-w-berberich

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 28 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 8 (Patent Applications = 7)

EPO Patents = 20 (Patent Applications = 24)

Average Co-Inventor Count = 4.3

ph-index = 6

Forward Citations = 87(Granted Patents)

Company Filing History:

28 out of 718

Mallinckrodt, Inc.

patents

Years Active: 2010-2020

Loading Chart...

Areas of Expertise:

Morphinan

Opiate Derivatives

Phototherapy

Synthesis Processes

Hexahydroisoquinolines

Alkaloids

Catalytic Hydrogen Transfer

N-alkyl Morphinans

Therapeutic Uses

Heterocyclic Rings

Buprenorphine

28 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10604488 - (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof (2020-03-31),

2. 10363251 - (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof (2019-07-30),

3. 9562014 - (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof (2017-02-07),

4. 8921561 - One-pot preparation of hexahydroisoquinolines from amides (2014-12-30),

5. 8829020 - Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers (2014-09-09),

6. 8703949 - Tandem process for preparing N-alkyl morphinans (2014-04-22),

7. 8624031 - Production of alkaloids without the isolation of intermediates (2014-01-07),

8. 8624030 - N-demethylation of 6-keto morphinans (2014-01-07),

9. 8623888 - 3-oxy-hydromorphone derivatives (2014-01-07),

10. 8614224 - Sinomenine derivatives and processes for their synthesis (2013-12-24),

11. 8563727 - (+)-morphinanium N-oxides and processes for their production (2013-10-22),

12. 8563725 - Preparation of saturated ketone morphinan compounds having low metal content (2013-10-22),

13. 8563724 - (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives (2013-10-22),

14. 8461337 - Sinomenine derivatives and processes for their synthesis (2013-06-11),

15. 8436174 - (+)-morphinanium quaternary salts and processes for their production (2013-05-07),

Title: David W. Berberich: Innovator in Pain Management

Introduction

David W. Berberich, an accomplished inventor based in St. Peters, MO, has made significant contributions to the field of pharmaceuticals. With a remarkable portfolio of 28 patents, his work focuses primarily on innovative solutions for pain management through novel compounds.

Latest Patents

Among his latest inventions are two notable patents involving (+)-morphinans as antagonists of Toll-like receptor 9 (TLR9). The first patent details the use of these compounds to treat pain, showcasing their antagonist activity against TLR9. It also describes pharmaceutical combination compositions that include a (+)-morphinan alongside an opioid agonist or monoamine reuptake inhibitor for effective pain treatment. The second patent expands on the therapeutic applications of (+)-morphinans in addressing various disorders, highlighting their potential in the pharmaceutical industry.

Career Highlights

David W. Berberich is currently employed at Mallinckrodt, Inc., where he continues to innovate in the realm of pain management therapies. His extensive work and research in drug development have positioned him as a leader in creating effective therapeutic options.

Collaborations

Throughout his career, Berberich has collaborated with notable professionals in his field, including Peter Xianqi Wang and Gary Lee Cantrell. These partnerships have undoubtedly contributed to the advancement of his research and the successful development of his patents.

Conclusion

David W. Berberich's expertise and dedication to innovation in pharmacology have resulted in significant advancements that address pain management and related disorders. His ongoing work at Mallinckrodt, Inc., along with his impressive patent portfolio, underscores his impact on the pharmaceutical industry.

Profile summary based on public USPTO records.